Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record.

Impact of initial aggressive drug treatment with a combination of disease‐modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five‐year randomized followup trial

Puolakka, Kari, Kautiainen, Hannu, Möttönen, Timo, Hannonen, Pekka, Korpela, Markku, Julkunen, Heikki, Luukkainen, Reijo, Vuori, Kaisa, Paimela, Leena, Blåfield, Harri, Hakala, Markku, Leirisalo‐Repo, Marjatta·2004·Arthritis & Rheumatism

Abstract

Objective: To compare the efficacy of therapy with a combination of disease‐modifying antirheumatic drugs (DMARDs) versus therapy with a single DMARD in the prevention of work disability in patients with early rheumatoid arthritis (RA). Methods: In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent‐onset RA were randomly assigned to receive either combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone or single therapy with a DMARD with or without prednisolone. After 2 years, the drug treatment strategy was no longer restricted. At baseline, 162 patients (80 in the combination‐treatment group and 82 in the single‐treatment group) were still working or at least available for work. After 5 years of followup, data on all sick leave and retirement were obtained from social insurance registers or case records. The main outcome for each patient was the cumulative duration of all sick leaves and RA‐related disability pensions, divided by the observation period during which the patient was not retired because of another disease or because of age. Results: The cumulative duration of work disability per patient‐observation year was significantly lower in those randomized to combination therapy than in those randomized to single therapy: median 12.4 days (interquartile range [IQR] 0–54) versus 32.2 days (IQR 6–293) (P = 0.008, sex‐ and age‐adjusted P = 0.009). This was mainly due to the difference in sick leaves (i.e., work disability periods ≤300 days): median 11.7 days (IQR 0–44) per patient‐observation year in those treated with combination therapy and 30.0 days (IQR 6–68) in those treated with single therapy (P = 0.002). No statistically significant difference was seen in RA‐related disability pensions. Conclusion: Aggressive initial treatment of RA with a combination of DMARDs improves 5‐year outcome in terms of lost productivity in patients with RA of recent onset.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.11436

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 177

Metadata

Authors
Puolakka, K., Kautiainen, H., Möttönen, T., Hannonen, P., Korpela, M., Julkunen, H., Luukkainen, R., Vuori, K., Paimela, L., Blåfield, H., Hakala, M., & Leirisalo‐Repo, M.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2004-01
Volume
50
Issue
1
Pages
55-62
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2078317963
Cited by
177
References
0
FWCI
13.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of initial aggressive drug treatment with a combination of disease‐modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five‐year randomized followup trial. https://app.cochat.ai/papers/10.1002/art.11436
The paper
Puolakka, K., Kautiainen, H., Möttönen, T., Hannonen, P., Korpela, M., Julkunen, H., Luukkainen, R., Vuori, K., Paimela, L., Blåfield, H., Hakala, M., & Leirisalo‐Repo, M. (2004). Impact of initial aggressive drug treatment with a combination of disease‐modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five‐year randomized followup trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.11436

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.